2-Aminoindane
1Provenance card
the boundary, as counts
Sources
2316 with DOI
1 strong · 16 moderate · 6 weak
Compilations
12026-05-11T01:28:50.174Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
28last ruled 2026-06-04
0 awaiting a ruling
Issued documents
42026-10-19T20:28:57.499Z
notice · info card · emergency
Searches
211 with no results
queries and counts on the build
Claims checked
6357 supported
57 supported · 6 not
Correspondence
0received
consent field ships in Phase 4
Edges
211
derivations recorded for this entity
Complete over 23 sources, 1 compilation, and 28 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/2-aminoindane/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-09-07srcThe metabolic fate of two new psychoactive substances - 2-aminoindane and N-methyl-2-aminoindane - studied in vitro and in vivo to support drug testing.
- 2026-09-07srcAminoindanes--the next wave of 'legal highs'?
- 2026-09-07srcAcute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.
- 2026-09-07src5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'.
- 2026-09-07src2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and alpha2-adrenergic receptors
- 2026-09-07srcPharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives.
- 2026-09-07srcPostmortem distribution and redistribution of MDAI and 2-MAPB in blood and alternative matrices
- 2026-09-07srcDeath following consumption of MDAI and 5-EAPB
- 2026-09-07srcEmerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats.
- 2026-09-07srcPharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2-aminoindane (MEAI): A new binge-mitigating agent.
- 2026-09-07srcFirst toxicity profile of 2-aminoindane and N-Methyl-2-aminoindane using in silico multi-approach.
- 2026-09-07srcCytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay.
- 2026-09-07srcDetermination of novel psychoactive substances in human saliva using capillary electrophoresis.
- 2026-09-07srcSimultaneous Determination of Amphetamine-Related New Psychoactive Substances in Urine by Gas Chromatography-Mass Spectrometry
- 2026-09-07srcSynthetic Aminoindanes: A Summary of Existing Knowledge.
- 2026-09-07srcBehavioral and Pharmacokinetics Studies of N-Methyl-2-Aminoindane (NM2AI) in Mice: An Aminoindane Briefly Used in the Illicit Drug Market.
- 2026-09-07srcSerotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic MDMA analogue.
- 2026-09-07srcNonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
- 2026-09-07srcStudies on the mechanism of p-chloroamphetamine neurotoxicity.
- 2026-09-07src2-Aminoindane legal status - China, Sweden, UK, Austria
- 2026-09-07src2-Aminoindane - PsychonautWiki
- 2026-09-07srcNCT05913752 - First in Human Study of CMND-100 (MEAI) in AUD
- 2026-09-07src2-Aminoindane Physical Properties
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal26 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-11revisionRevision 1
- 2026-05-11absenceSearched PMC — no results
- 2026-05-11genGeneration — pipeline-v5 · with 1 morepipeline-v5
- 2026-05-11rungeneration run
The same entries, as forms: six forms.